Stoke Therapeutics Inc (STOK) Stock Price, Quote & News

Company Profile

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevun...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 430 8200

Website: www.stoketherapeutics.com

Address:

45 Wiggins Avenue, Bedford, United States

Sambo87 Jul. 10 at 7:58 PM

$STOK

0 · Reply

Doozio Jul. 4 at 4:33 PM

Chop chop n da list of $STOK s getting nice n tight waiting on poppa huckleberry 🐒🍌🧠⏰♾️

0 · Reply

JarvisFlow Jul. 1 at 10:30 AM

Needham updates rating for Stoke Therapeutics ( $STOK ) to Buy, target set at 22.

0 · Reply

LadsAndGents Jun. 23 at 4:18 PM

$STOK was that 1 share two times a manipulation? Feeling time to fly soon? Who is the new CEO?? $XBI $SPY

1 · Reply

LadsAndGents Jun. 17 at 11:19 AM

$VERV in talks with Lilly, board member is. CMO at $STOK interesting $XBI $SPY

0 · Reply

Alpha_Ascendant Jun. 16 at 11:28 AM

$STOK My new "Editor's Pick" report on Stoke Therapeutics, a tiny biotech that is pioneering RNA-based therapies, with a lead candidate for Dravet Syndrome and very big backing from $BIIB and $ACAD: https://seekingalpha.com/article/4795033-stoke-therapeutics-impressive-pipeline-and-big-backers

0 · Reply

DayTraderGeorge Jun. 6 at 2:39 PM

$STOK https://www.sec.gov/Archives/edgar/data/1623526/000031506625001629/xslSCHEDULE_13G_X01/primary_doc.xml

0 · Reply

G101SPM Jun. 4 at 11:39 AM

#NOISE $STOK Stoke Therapeutics provides certain updates related to the Company’s Phase 3 EMPEROR study of zorevunersen; initiated the Phase 3 EMPEROR study with the first United States sites initiated in May 2025

0 · Reply

G101SPM Jun. 4 at 11:09 AM

$STOK Stoke Therapeutics provides certain updates related to the Company’s Phase 3 EMPEROR study of zorevunersen; initiated the Phase 3 EMPEROR study with the first United States sites initiated in May 2025

0 · Reply

conservativeaviator Jun. 3 at 4:52 PM

$STOK well, well ,well. look who woke up.

0 · Reply

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

BIIB

Jul 10, 2025, 7:00 AM EDT - 5 days ago

Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

BIIB

Jun 17, 2025, 4:30 PM EDT - 27 days ago

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 15, 2025, 11:27 PM EDT - 4 weeks ago

Stoke Therapeutics: Impressive Pipeline And Big Backers

May 29, 2025, 7:30 AM EDT - 6 weeks ago

Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference

May 13, 2025, 7:00 AM EDT - 2 months ago

Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 1, 2025, 4:30 PM EDT - 3 months ago

Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 18, 2025, 12:56 PM EDT - 4 months ago

Stoke Therapeutics Stock Slips as CEO Steps Down

Mar 18, 2025, 7:00 AM EDT - 4 months ago

Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 18, 2025, 6:58 AM EDT - 4 months ago

Stoke Therapeutics Announces CEO Transition

Feb 26, 2025, 4:30 PM EST - 4 months ago

Stoke Therapeutics to Present at Upcoming Investor Conferences in March

Feb 18, 2025, 8:46 AM EST - 5 months ago

Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy

BIIB

$Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments$

Feb 18, 2025, 8:00 AM EST - 5 months ago

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

BIIB

Feb 16, 2025, 2:23 PM EST - 5 months ago

Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer

Jan 8, 2025, 4:30 PM EST - 6 months ago

Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 7:00 AM EST - 6 months ago

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Jan 6, 2025, 4:30 PM EST - 6 months ago

Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome

Dec 6, 2024, 12:00 PM EST - 7 months ago

Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Dec 5, 2024, 8:30 AM EST - 7 months ago

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

BIIB PRAX WGS

Dec 4, 2024, 7:00 AM EST - 7 months ago

Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome

Dec 2, 2024, 8:00 AM EST - 8 months ago

Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting

Nov 5, 2024, 7:00 AM EST - 9 months ago

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

Sep 10, 2024, 7:00 AM EDT - 11 months ago

Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome

Sep 7, 2024, 4:03 AM EDT - 11 months ago

Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome

Sep 4, 2024, 8:00 AM EDT - 11 months ago

Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

Sep 3, 2024, 8:00 AM EDT - 11 months ago

Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Sep 3, 2024, 8:00 AM EDT - 11 months ago

Stoke Therapeutics to Present at Upcoming Investor Conferences in September

Aug 16, 2024, 4:30 PM EDT - 11 months ago

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

Jun 24, 2024, 3:32 AM EDT - 1 year ago

Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday

EPAC OMIC ITI XAIR

Jun 14, 2024, 12:10 PM EDT - 1 year ago

Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome

Jun 3, 2024, 4:30 PM EDT - 1 year ago

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

May 6, 2024, 7:00 AM EDT - 1 year ago

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

Apr 29, 2024, 8:00 AM EDT - 1 year ago

Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer

Apr 17, 2024, 8:00 AM EDT - 1 year ago

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

Apr 4, 2024, 4:30 PM EDT - 1 year ago

Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 27, 2024, 11:40 PM EDT - 1 year ago

Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering

Mar 26, 2024, 4:07 PM EDT - 1 year ago

Stoke Therapeutics Announces Proposed Public Offering

Mar 25, 2024, 4:01 PM EDT - 1 year ago

Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome

Mar 25, 2024, 4:01 PM EDT - 1 year ago

Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Jan 8, 2024, 8:00 AM EST - 1 year ago

Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024

Jan 4, 2024, 4:30 PM EST - 1 year ago

Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 1, 2023, 9:00 AM EST - 1 year ago

Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting

Nov 21, 2023, 8:00 AM EST - 1 year ago

Stoke Therapeutics to Present Data from the Company's Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting

Sep 21, 2023, 8:00 AM EDT - 1 year ago

Stoke Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

Sep 20, 2023, 4:30 PM EDT - 1 year ago

Stoke Therapeutics Appoints Ian Smith to its Board of Directors

Sep 10, 2023, 5:08 PM EDT - 2 years ago

Stoke Therapeutics Is Unable To Derisk Its Platform

Sep 5, 2023, 7:00 AM EDT - 2 years ago

Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress

Aug 2, 2023, 8:00 AM EDT - 2 years ago

Stoke Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

Jul 25, 2023, 7:00 AM EDT - 2 years ago

Stoke Therapeutics Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome

Sambo87 Jul. 10 at 7:58 PM

$STOK

0 · Reply

Doozio Jul. 4 at 4:33 PM

Chop chop n da list of $STOK s getting nice n tight waiting on poppa huckleberry 🐒🍌🧠⏰♾️

0 · Reply

JarvisFlow Jul. 1 at 10:30 AM

Needham updates rating for Stoke Therapeutics ( $STOK ) to Buy, target set at 22.

0 · Reply

LadsAndGents Jun. 23 at 4:18 PM

$STOK was that 1 share two times a manipulation? Feeling time to fly soon? Who is the new CEO?? $XBI $SPY

1 · Reply

LadsAndGents Jun. 17 at 11:19 AM

$VERV in talks with Lilly, board member is. CMO at $STOK interesting $XBI $SPY

0 · Reply

Alpha_Ascendant Jun. 16 at 11:28 AM

0 · Reply

DayTraderGeorge Jun. 6 at 2:39 PM

$STOK https://www.sec.gov/Archives/edgar/data/1623526/000031506625001629/xslSCHEDULE_13G_X01/primary_doc.xml

0 · Reply

G101SPM Jun. 4 at 11:39 AM

0 · Reply

G101SPM Jun. 4 at 11:09 AM

0 · Reply

conservativeaviator Jun. 3 at 4:52 PM

$STOK well, well ,well. look who woke up.

0 · Reply

LadsAndGents May. 27 at 11:23 PM

$STOK Lilly acquired Siteone Tx for $1 Billion (not even IPO) working on Nav1.7 and no Lover for Nav1.1 ? Next one year could belong here $XBI

2 · Reply

LadsAndGents May. 13 at 4:56 PM

$STOK

0 · Reply

LadsAndGents May. 13 at 1:57 AM

$STOK when FT CEO ?? Show us the face

0 · Reply

Armonica423 May. 7 at 2:13 AM

$STOK CYDY

1 · Reply

DonMclean64 May. 6 at 7:59 PM

$STOK anyone know what happened?

1 · Reply

LadsAndGents May. 6 at 5:06 PM

$STOK

0 · Reply

LadsAndGents May. 6 at 2:36 PM

$STOK 2.6K here for short term

0 · Reply

LadsAndGents Apr. 29 at 2:43 PM

$STOK

0 · Reply

PenkeTrading Apr. 25 at 2:43 PM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Stoke Therapeutics Inc. Is that bullish or bearish? $STOK #Stoke #RsiOverbought #NASDAQ

0 · Reply

50bps Apr. 23 at 2:16 PM

$STOK 👀

0 · Reply

kenny91655 Apr. 22 at 3:55 PM

$STOK Sold half.

1 · Reply

Stocks4thought Apr. 21 at 2:09 PM

$STOK Dude where's my car$

1 · Reply

Market Cap	647.52M
Revenue (ttm)	36.56M
Net Income (ttm)	-88.98M
EPS (ttm)	N/A
PE Ratio	15.24
Forward PE	N/A
Profit Margin	-243.38%
Debt to Equity Ratio	0.00

Volume	411,423
Avg Vol	615,362
Day's Range	N/A - N/A
Shares Out	54.60M
Stochastic %K	69%
Beta	1.14
Analysts	Strong Sell
Price Target	$22.38